Results 91 to 100 of about 12,288 (265)

Adverse Events and Immunization Errors Following a Mass Immunization Campaignwith TAK‐003 in Dourados, Brazil: A Post‐Marketing Safety Surveillance Analysis

Journal of Medical Virology, Volume 97, Issue 11, November 2025.
ABSTRACT This descriptive observational study based on post‐marketing surveillance data evaluates adverse events following immunization (AEFI) associated with the TAK‐003 (Qdenga®) vaccine. Conducted in Dourados, Brazil, between January and November 2024, the study aimed to assess the frequency, nature, and severity of AEFI to inform public health ...
Luana Clemm Kuhnen Anschau, Amanda Maria Miguel Bortuluzi, Andrea da Silva Santos, Devanildo de Souza Santos, Sandra de Souza Rodrigues, Indianara Ramires Machado, Renato de Ávila Kfouri, Marco Aurélio Palazzi Sáfadi, Roberto Dias de Oliveira, Julio Croda   +9 more
wiley   +1 more source

Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations

Vaccines, 2023
To compare immunogenicity and reactogenicity of five COVID-19 vaccine regimens against wild-type SARS-CoV-2 and variants of concern (VoCs) among Thai populations, a prospective cohort study was conducted among healthy participants aged ≥18 years who had ...
Tavitiya Sudjaritruk, Oramai Mueangmo, Jutamad Saheng, Poramed Winichakoon, Parichat Salee, Worawan Wongjak, Tanachot Chaito, Jutarat Praparattanapan, Khanuengnit Nuket, Nuttarika Solai, Jiraprapa Wipasa, Kriangkrai Chawansuntati, Romanee Chaiwarith   +12 more
doaj   +1 more source

Systemic drug‐related intertriginous and flexural exanthema like eruption after CoronaVac vaccine [PDF]

, 2021
Özge Mine Örenay, İlknur Balta, Dilek Yiğit, Meral Ekşioğlu   +3 more
openalex   +1 more source

Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries [PDF]

, 2022
Background: Scarce information exists in relation to the comparison of seroconversion and adverse events following immunization (AEFI) with different SARS-CoV-2 vaccines. Our aim was to correlate the magnitude of the antibody response to vaccination with
Acciardi C., Armendariz-Vazquez A. G., Azzolini E., Barbieri R., Barco-Flores I. A., Bastos-Borges A., de Azevedo Dias A. R., Del Rio-Parra G. F., Gonzalez-Cantu A., Gonzalez-Facio R., Henriques Guimaraes Junior M., Hernandez-Ruiz Y. G., Levi R., Mollura M., Paez-Bo G., Pozzi C., Rescigno M., Rivera-Salinas D., Romero-Ibarguengoitia M. E., Sanz-Sanchez M. A., Sarti R., Teixeira M. M.   +21 more
core   +1 more source

One‐Year Quality of Life Among Survivors of Hospitalization for Omicron Infection in Brazil: A Multicentre Prospective Cohort Study

Journal of Medical Virology, Volume 97, Issue 11, November 2025.
ABSTRACT The lingering effects of COVID‐19 may impair survivors' long‐term health‐related quality of life (HRQoL). However, multicentre studies focusing on the Omicron variant, particularly in middle‐ and low‐income settings, are scarce. We conducted a prospective cohort study across 24 Brazilian hospitals between December 2021 and March 2024, when ...
Geraldine Trott, Marciane Maria Rover, Fernando Luis Scolari, Mariana Motta Dias da Silva, Denise de Souza, Rosa da Rosa Minho dos Santos, Raíne Fogliati De Carli, Emelyn de Souza Roldão, Gabriela Soares Rech, Duane Mocellin, Jennifer Menna Barreto de Souza, Aline Paula Miozzo, Carolina Rothmann Itaqui, Gabrielle Nunes da Silva, Sergio Renato da Rosa Decker, Erica Neves Leite, Carlos Delmar do Amaral Ferreira, Lucas Gobetti da Luz, Gabriel Beilfuss Rieth, Lucas Tramujas, Fernando Azevedo Medrado, Bruna Fornazieri Piotto, Gizelle Fernanda Oliveira Silva, Josafá Ferreira Chaves, Saionara Cristina Francisco, Precil Diego Miranda de Menezes Neves, Victor Augusto Hamamoto Sato, Viviane Cordeiro Veiga, Kaique Lima Martins, Cláudio Dornas de Oliveira, Sabrina Gomes dos Santos, Juliana Cardozo Fernandes, Thiago Costa Lisboa, Vivian Menezes Irineu, Mauricio Antonio Pompilio, Adriana de Oliveira França, Aline Coletto Jaccottet, Juliana Carvalho Schleder, Vinicius Ortigosa Nogueira, Vandack Nobre, Daniel Souto Silveira, Cézar Eumann Mesas, Diego Miltersteiner, Emanuelle Toledo Ortiz, Fernando Gioppo Blauth, Luciane Maria Facchi, Milena Soriano Marcolino, Ana Carolina Peçanha Antonio, Paulo R. Schvartzman, Bruna Brandão Barreto, Caroline Cabral Robinson, Maicon Falavigna, Carisi Anne Polanczyk, Luiz Antonio Nasi, Regis Goulart Rosa, Post‐Covid Brasil 1 Group Autorship   +55 more
wiley   +1 more source

Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study

COVID, 2022
The ongoing COVID-19 pandemic remained a major public health concern despite a large-scale deployment of vaccines. One of the vaccines is CoronaVac, an inactivated vaccine. The efficacy of the vaccine was estimated at 50.7–83.5% in clinical trials. However, the real-world efficacy often differed.
Sri Masyeni, Edison Johar, Anak Agung Gede Budhitresna, Nyoman Mahardika, Nyoman Ratna Kartika Dewi, I Gde Raka Widiana, Frilasita Aisyah Yudhaputri, Khin Saw Aye Myint   +7 more
openaire   +1 more source

Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study

Emerging Microbes and Infections, 2023
Severe COVID-19 appears to be disproportionately more common in children and adolescents since the emergence of Omicron. More evidence regarding vaccine effectiveness (VE) is urgently needed to assist policymakers in making decisions and minimize vaccine
Vincent Ka Chun Yan, Franco Wing Tak Cheng, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Carlos King Ho Wong, Xue Li, Eric Yuk Fai Wan, Joshua Sung Chih Wong, Esther Wai Yin Chan, Ian Chi Kei Wong, Mike Yat Wah Kwan, Patrick Ip   +11 more
doaj   +1 more source

Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study [PDF]

, 2023
Min Fan, Francisco Tsz Tsun Lai, Franco Wing Tak Cheng, Natalie Tsz Ying Tsie, Xue Li, Eric Yuk Fai Wan, Carlos King Ho Wong, Esther W. Chan, Kai Hang Yiu, Ian Chi Kei Wong, Celine Sze Ling Chui   +10 more
openalex   +1 more source

Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination [PDF]

, 2022
Vaccination is a fundamental tool to prevent SARS-CoV-2 infection and to limit the COVID-19 pandemic. The emergence of SARS-CoV-2 variants with multiple mutations has raised serious concerns about the ability of neutralizing antibody responses elicited ...
Honorato, Layla, Mendes-Correa, Maria Cassia, Paula, Anderson de, Silva Jr, Almir Ribeiro da, Tozetto-Mendoza, Tania Regina, Villas-Boas, Lucy Santos, Witkin, Steven S.   +6 more
core   +2 more sources

SARS‐CoV‐2 Spike Protein as a Target of the COVID‐19 Vaccine Disrupts Insulin Signaling in Type 2 Diabetes

MedComm, Volume 6, Issue 11, November 2025.
SARS Cov‐2 spike protein disrupts insulin signaling in type 2 diabetes as a target of the COVID‐19 vaccine in subject with type 2 diabetes (T2D), while metformin improved the insulin signaling variations induced by mRNA COVID‐19 vaccine boosters in mice.
Lixiang Zhai, Min Zhuang, Hoi Ki Wong, Chengyuan Lin, Haoran Ying, Jialing Zhang, Gengyu Bao, Yijing Zhang, Shujun Xu, Jingyuan Luo, Shuofeng Yuan, Hoi Leong Xavier Wong, Zhao‐Xiang Bian   +12 more
wiley   +1 more source